NASDAQ:LIVN • GB00BYMT0J19
The current stock price of LIVN is 65.8 USD. In the past month the price increased by 4.13%. In the past year, price increased by 38%.
ChartMill assigns a technical rating of 10 / 10 to LIVN. When comparing the yearly performance of all stocks, LIVN is one of the better performing stocks in the market, outperforming 85.45% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to LIVN. LIVN has only an average score on both its financial health and profitability.
Over the last trailing twelve months LIVN reported a non-GAAP Earnings per Share(EPS) of 3.85. The EPS increased by 12.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.5% | ||
| ROE | -18.78% | ||
| Debt/Equity | 0.3 |
17 analysts have analysed LIVN and the average price target is 73.19 USD. This implies a price increase of 11.23% is expected in the next year compared to the current price of 65.8.
For the next year, analysts expect an EPS growth of 16.86% and a revenue growth 10.7% for LIVN
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.62 | 195.936B | ||
| ISRG | INTUITIVE SURGICAL INC | 47.53 | 172.536B | ||
| SYK | STRYKER CORP | 24.21 | 139.985B | ||
| BSX | BOSTON SCIENTIFIC CORP | 21.34 | 110.826B | ||
| IDXX | IDEXX LABORATORIES INC | 42.48 | 50.254B | ||
| BDX | BECTON DICKINSON AND CO | 11.16 | 50.113B | ||
| EW | EDWARDS LIFESCIENCES CORP | 25.52 | 44.027B | ||
| RMD | RESMED INC | 20.57 | 36.792B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16 | 36.615B | ||
| DXCM | DEXCOM INC | 27.73 | 27.309B |
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. The firm designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
LIVANOVA PLC
20 Eastbourne Terrace
London W2 6LG GB
CEO: Damien McDonald
Employees: 2900
Phone: 442033250662
LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. The firm designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
The current stock price of LIVN is 65.8 USD. The price increased by 2.96% in the last trading session.
LIVN does not pay a dividend.
LIVN has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
The PE ratio for LIVANOVA PLC (LIVN) is 17.09. This is based on the reported non-GAAP earnings per share of 3.85 and the current share price of 65.8 USD.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on LIVN.
LIVANOVA PLC (LIVN) currently has 2900 employees.